BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xu H, Wang M, Li Y, Shi M, Wang Z, Cao C, Hong Y, Hu B, Zhu H, Zhao Z, Chu X, Zhu F, Deng X, Wu J, Zhao F, Guo J, Wang Y, Pei G, Zhu F, Wang X, Yang J, Yao Y, Zeng R. Blocking connexin 43 and its promotion of ATP release from renal tubular epithelial cells ameliorates renal fibrosis. Cell Death Dis 2022;13:511. [PMID: 35641484 DOI: 10.1038/s41419-022-04910-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhao Z, Li G, Wang Y, Li Y, Xu H, Liu W, Hao W, Yao Y, Zeng R. Cytoplasmic HMGB1 induces renal tubular ferroptosis after ischemia/reperfusion. Int Immunopharmacol 2023;116:109757. [PMID: 36731154 DOI: 10.1016/j.intimp.2023.109757] [Reference Citation Analysis]
2 Liu J, Liu S, Hu S, Lu J, Wu C, Hu D, Zhang W. ATP ion channel P2X purinergic receptors in inflammation response. Biomedicine & Pharmacotherapy 2023;158:114205. [DOI: 10.1016/j.biopha.2022.114205] [Reference Citation Analysis]
3 Kiełbowski K, Bakinowska E, Pawlik A. The Potential Role of Connexins in the Pathogenesis of Atherosclerosis. IJMS 2023;24:2600. [DOI: 10.3390/ijms24032600] [Reference Citation Analysis]
4 Roger E, Boutin L, Chadjichristos CE. The Role of Connexin 43 in Renal Disease: Insights from In Vivo Models of Experimental Nephropathy. IJMS 2022;23:13090. [DOI: 10.3390/ijms232113090] [Reference Citation Analysis]
5 Jasmer KJ, Muñoz Forti K, Woods LT, Cha S, Weisman GA. Therapeutic potential for P2Y2 receptor antagonism. Purinergic Signal 2022. [PMID: 36219327 DOI: 10.1007/s11302-022-09900-3] [Reference Citation Analysis]
6 Lu Y, Zhang Z, Wu H, Fang L, Hu B, Tang C, Zhang Y, Yin L, Tang D, Zheng Z, Zhu T, Dai Y. SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease. J Transl Med 2022;20. [DOI: 10.1186/s12967-022-03629-8] [Reference Citation Analysis]